EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF PATIENTS WITH PSORIASIS TREATED WITH BIOLOGICAL AGENTS COMPARED TO THOSE USING OTHER TREATMENT METHODS
Main Article Content
Abstract
Objective: To investigate the epidemiological and clinical characteristics of patients with moderate-to-severe psoriasis vulgaris treated with biological agents, compared to those using other treatment methods. Subjects and Methods: A case series study was conducted at HCMC Hospital of Dermatology and Venereology, involving 253 participants from March 2024 to June 2024. Results: Patients receiving biologics were generally older, had a higher male-to-female ratio, and had higher educational and income levels than those in other treatment groups. Biologic treatment was associated with a longer disease duration and significantly greater treatment efficacy, evidenced by lower PASI, BSA, and DLQI scores. In contrast, patients in the non-biologic treatment group predominantly used topical medications (97.5%) and conventional systemic therapies (60.8%). The primary barrier to biologic therapy was its high cost, as reported by 75.8% of patients. Conclusion: Biologics were shown to be an effective treatment option, leading to high patient satisfaction. The study highlighted notable differences in socioeconomic status and treatment outcomes between patients treated with biologics and those using other therapies.
Article Details
Keywords
socioeconomic, psoriasis, biologics
References
2. Mansouri Y, Goldenberg G. Biologic safety in psoriasis: review of long-term safety data. J Clin Aesthet Dermatol. Feb 2015;8(2):30-42.
3. Norlin JM, Löfvendahl S, Schmitt-Egenolf M. The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis. J Clin Med. Nov 22 2023;12(23)doi:10.3390/jcm12237234
4. Scala E, Megna M, Amerio P, et al. Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS One. 2020;15(8):e0237267. doi:10.1371/journal.pone.0237267
5. Geale K, Henriksson M, Schmitt-Egenolf M. Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics. British Journal of Dermatology. 2016;174(3): 579-587. doi:https://doi.org/10. 1111/bjd.14331
6. Gudjonsson JE, Elder JT. Psoriasis. In: Kang S, Amagai M, Bruckner AL, et al, eds. Fitzpatrick's Dermatology, 9e. McGraw-Hill Education; 2019.
7. Min S, Wang D, Xia J, et al. The economic burden and quality of life of patients with psoriasis treated with biologics in China. J Dermatolog Treat. Dec 2023;34(1):2247106. doi:10.1080/09546634.2023.2247106